Atara Biotherapeutics Inc ( (ATRA) ) has released its Q3 earnings. Here is a breakdown of the information Atara Biotherapeutics Inc presented ...

SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix ...

Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ...

Artiva Biotherapeutics, Inc. ( (ARTV) ) has released its Q3 earnings. Here is a breakdown of the information Artiva Biotherapeutics, Inc.

Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a <a target ...

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Collaboration Revenue - Collaboration revenue was $1.1 million for the quarter ended September 30, 2024, compared to $2.5 ...

Shares of Calidi Biotherapeutics surged after the immuno-oncology company reported quarterly results but lost some of their gains after it announced a proposed stock offering. The stock gained 60% to ...

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company ...

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have ...